In the UK, 1 in 5 people are directly affected by respiratory disease, costing the NHS £11 billion annually.

RNA therapeutics comprise of a rapidly expanding category of drugs that possess the potential to change the standard of care for respiratory disease and actualize personalized medicine.

Learn more about the current challenges and future opportunities across RNA and respiratory disease in our discussion with Dr Rocio T Martinez-Nunez.

The COVID-19 RNA vaccines have paved the way for us to see that RNA is a therapeutic possibility. They proved to be the perfect case study for tolerability, safety and speed of development.

Dr Rocio T Martinez-Nunez